Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that has become one of the most widely published research compounds in metabolic science over the past decade. This article summarizes the publicly available clinical research — not as a recommendation, but as an educational overview of what the published literature reports. This overview specifically addresses semaglutide research, and related research is indexed on PubMed.
Mechanism of Action
GLP-1 is an incretin hormone naturally produced by the intestinal L-cells in response to food intake. Semaglutide mimics GLP-1 with a 94% structural similarity but has been modified for longer half-life — roughly 7 days compared to native GLP-1’s 2-minute half-life.
The key mechanisms investigated in published research include:
- Glucose-dependent insulin secretion: Stimulates insulin release only when blood glucose is elevated, reducing hypoglycemia risk compared to older agents
- Glucagon suppression: Reduces hepatic glucose output by suppressing glucagon release during meals
- Gastric emptying: Slows gastric motility, contributing to reduced caloric intake in study subjects
- Central appetite signaling: Acts on hypothalamic receptors to influence satiety signaling — this CNS pathway is increasingly a focus of research interest
- Cardiovascular pathways: GLP-1 receptors are expressed in cardiac tissue; multiple trials have investigated direct and indirect cardiovascular effects
The SUSTAIN Trial Series
The SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) ran from 2014 to 2019 and included 8 major randomized controlled trials with over 8,000 participants. Key findings reported in the published literature:
SUSTAIN-6 (Cardiovascular Outcomes)
3,297 high-risk participants. Published in NEJM (2016). Reported a 26% relative reduction in the composite of cardiovascular death, nonfatal MI, and nonfatal stroke. This was the first large RCT demonstrating CV benefit in this compound class, driving significant follow-on research interest.
SUSTAIN-7 (Head-to-Head vs Dulaglutide)
1,201 participants. Published in Lancet Diabetes & Endocrinology (2018). Semaglutide 0.5mg and 1.0mg showed greater HbA1c and body weight reductions compared to dulaglutide at matched doses. The 1.0mg dose showed ~6.5kg mean body weight reduction vs ~3.0kg for dulaglutide 1.5mg.
The STEP Trial Series
The STEP program studied subcutaneous semaglutide 2.4mg (higher dose than SUSTAIN) specifically for body composition outcomes in non-diabetic adults with obesity. Four major trials, ~4,500 total participants.
STEP-1 — The Landmark Trial
1,961 participants, 68 weeks. Published in NEJM (2021). Participants receiving semaglutide 2.4mg reported a mean 14.9% reduction in body weight vs 2.4% placebo. 86.4% of the semaglutide group achieved at least 5% weight reduction; 69.1% achieved at least 10%.
These were unprecedented numbers in published obesity pharmacotherapy research at the time, driving an enormous wave of follow-on research and industry investment in this class.
STEP-2 (Type 2 Diabetes Subgroup)
1,210 participants with T2D. Published in Lancet (2021). Mean weight reduction of 9.6% at 68 weeks vs 3.4% placebo. HbA1c reduction of 1.6% at the 2.4mg dose.
SELECT Trial — Cardiovascular Outcomes Without Diabetes
Published in NEJM (2023), SELECT enrolled 17,604 participants with established cardiovascular disease but without diabetes. Mean follow-up 39.8 months. Reported 20% reduction in the composite of CV death, nonfatal MI, and nonfatal stroke. This was notable because the benefit appeared independent of degree of weight loss, suggesting direct vascular mechanisms beyond body composition changes.
Ongoing Research Areas
Active areas in the published literature as of 2025–2026:
- Neurological applications: FOCUS (Parkinson’s), EVOKE (Alzheimer’s) — GLP-1 receptors in the brain may play neuroprotective roles
- MASH/NASH: Multiple trials investigating hepatic steatosis and inflammation pathways
- Sleep apnea: SURMOUNT-OSA data showing improvements in apnea-hypopnea index
- Addiction and reward pathways: Preclinical data on dopaminergic pathways; early human trials on alcohol and substance use
- Kidney protection: FLOW trial (semaglutide in chronic kidney disease) showing 24% reduction in kidney disease progression
Research Context and Compliance Note
All data referenced above is from published peer-reviewed literature available in PubMed, NEJM, and Lancet databases. This content is educational context only — not medical advice, not a dosing recommendation, and not an endorsement of any commercial product. Semaglutide is FDA-approved as a prescription medication (Ozempic, Wegovy) and should only be used under medical supervision for approved indications.
Researchers studying this compound class in RUO (research use only) contexts should review full IRB requirements and applicable jurisdiction regulations.
STEP-4: What Happens After Stopping Semaglutide
A frequently overlooked but important piece of the semaglutide evidence base is STEP-4, a randomized withdrawal trial published in JAMA in 2022 (Rubino et al.). In this trial, participants first received semaglutide 2.4mg for 20 weeks (all achieving substantial initial weight loss), then were randomized to either continue semaglutide or switch to placebo for an additional 48 weeks. Participants who continued semaglutide lost an additional 7.9% body weight on average during the extension period. Participants switched to placebo regained an average of 6.9 percentage points of body weight during the same period — meaning most of the weight-loss benefit was not durable once the medication was discontinued. This finding is central to how the clinical and research community now frames GLP-1 therapy: as a treatment for a chronic condition requiring ongoing therapy to maintain effect, similar to how other chronic-disease medications function, rather than a finite course of treatment with a durable standalone effect after stopping.
Frequently Asked Questions
Does weight loss from semaglutide persist after stopping the medication?
Published withdrawal trial data (STEP-4) shows the majority of weight-loss benefit is not maintained after discontinuation — participants who stopped and switched to placebo regained a substantial portion of the weight lost during treatment over the following year.
Does this mean semaglutide “doesn’t really work”?
No — it means the mechanism (appetite and satiety signaling via GLP-1 receptor activation) requires ongoing receptor engagement to sustain its effect, similar to how blood pressure or cholesterol medications require continued use to maintain their effect. This is a pharmacological property of the drug class, not evidence against its efficacy while being used.
Should someone plan to take semaglutide indefinitely?
This is a clinical decision between a patient and their prescribing physician based on individual goals, health status, and how the medication is being used — the STEP-4 data is relevant context for that conversation, not a general recommendation for or against long-term use.
Key References
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844. DOI: 10.1056/NEJMoa1607141
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. DOI: 10.1056/NEJMoa2307563
- Perkovic V, et al. Semaglutide in Patients with Chronic Kidney Disease. N Engl J Med. 2024;391:109-121.
